Makena

GPTKB entity

Statements (55)
Predicate Object
gptkbp:instance_of gptkb:pharmaceuticals
gptkbp:approves gptkb:2011
gptkbp:brand gptkb:Makena
gptkbp:category Category B
gptkbp:clinical_trial Phase III
conducted in multiple countries
reduced risk of complications
conducted in Australia
conducted in Asia
conducted in Canada
conducted in Europe
conducted in the United States
improved neonatal outcomes
shown to reduce preterm birth rates
gptkbp:clinical_use given to women with a history of preterm birth
gptkbp:condition premature birth
preterm labor
gptkbp:contraindication allergy to hydroxyprogesterone
gptkbp:dosage_form solution for injection
gptkbp:effective_date FDA approved
gptkbp:formulation oil-based solution
gptkbp:frequency once a week
gptkbp:generic_availability no generic available
https://www.w3.org/2000/01/rdf-schema#label Makena
gptkbp:ingredients gptkb:hydroxyprogesterone_caproate
gptkbp:invention patented
gptkbp:manufacturer gptkb:AMAG_Pharmaceuticals
gptkbp:marketed_as gptkb:Makena
gptkbp:mechanism_of_action progestin hormone
gptkbp:packaging single-dose vial
gptkbp:patient_education importance of adherence to treatment
informed about potential side effects
monitoring for signs of complications
gptkbp:patient_population pregnant women at risk of preterm delivery
gptkbp:price varies by pharmacy
gptkbp:provides_guidance_on ACOG guidelines recommend use
gptkbp:regulatory_compliance approved by FDA
approved by EMA
gptkbp:related_products gptkb:17-alpha-hydroxyprogesterone
progesterone
gptkbp:research studies on long-term effects
studies on safety profile
studies on efficacy in multiple pregnancies
gptkbp:route_of_administration intramuscular injection
gptkbp:side_effect headache
nausea
hypertension
injection site reactions
gestational diabetes
thromboembolic disorders
gptkbp:storage store at room temperature
gptkbp:type_of_insurance may be covered by insurance
gptkbp:used_for prevention of preterm birth
gptkbp:bfsParent gptkb:South_Maui
gptkbp:bfsLayer 6